Local Tech Wire

MORRISVILLE, N.C. – has received a patent from the U.S. Patent and Trademark Office for the drug Rifaximin, the company announced on Thursday.

This patent will provide protection until August 2019 for rifaximin relating to a method of treating a subject suffering from irritable bowel syndrome. Salix currently is assessing the use of Rifaximin in the treatment of IBS.

Salix (NASDAQ:SLXP) markets the drug in the U.S. as Xifaxan and Xifaxan550. The company has an exclusive license to the patent from Cedars-Sinai Medical Center to make use, sell and import licensed products related to the use of Rifaximin.

Get the latest news alerts: at Twitter.